DATOPOTAMAB DERUXTECAN-DLNK for Product used for unknown indication: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 30 adverse event reports in the FDA FAERS database where DATOPOTAMAB DERUXTECAN-DLNK was used for Product used for unknown indication.
Most Reported Side Effects for DATOPOTAMAB DERUXTECAN-DLNK
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Disease progression | 49 | 29.7% | 25 | 8 |
| Off label use | 31 | 18.8% | 8 | 6 |
| Stomatitis | 27 | 16.4% | 3 | 4 |
| No adverse event | 22 | 13.3% | 0 | 0 |
| Nausea | 11 | 6.7% | 4 | 3 |
| Prescribed underdose | 9 | 5.5% | 7 | 0 |
| Death | 7 | 4.2% | 7 | 0 |
| Interstitial lung disease | 7 | 4.2% | 1 | 3 |
| Dyspnoea | 6 | 3.6% | 0 | 4 |
| Mucosal inflammation | 5 | 3.0% | 0 | 2 |
| Product prescribing issue | 5 | 3.0% | 0 | 0 |
Other Indications for DATOPOTAMAB DERUXTECAN-DLNK
Hormone receptor positive her2 negative breast cancer (55)
Breast cancer (27)
Breast cancer metastatic (13)
Non-small cell lung cancer (10)
Lung neoplasm malignant (8)
Triple negative breast cancer (6)
Other Drugs Used for Product used for unknown indication
OXYCODONE (129,391)
ADAPALENE (91,681)
APIXABAN (88,417)
ETANERCEPT (71,866)
SACUBITRIL\VALSARTAN (69,693)
ACETAMINOPHEN (68,427)
AVOBENZONE\OCTISALATE\OCTOCRYLENE (65,206)
ADALIMUMAB (63,549)
EVOLOCUMAB (60,696)
MORPHINE (59,440)